



Interest from potential partners and positive response to ALZ-101 at the AD/PD™ conference

Alzinova AB (publ) (“Alzinova” or the “Company”) presented data from studies with the Company's vaccine candidate ALZ-101 at the international Alzheimer conference AD/PD™ held in Gothenburg, March 28 - April 1 2023. The scientific poster shows that the vaccine candidate has a long-term effect and that antibodies are found in the brain in the expected amount. The results attracted great interest at the conference and several important contacts were established.

Alzinova's Chief Scientific Officer Anders Sandberg presented a scientific poster at the conference summarizing preclinical data for the Company's vaccine candidate ALZ-101 (phase 1b study ongoing). The conclusion presented is that ALZ-101 stimulates the production of antibodies for a long time, and that these can reach the brain in relevant amounts. The vaccine thus seems to be effective also as a long-term treatment (chronic treatment) for Alzheimer's disease. The presentation sparked great interest and resulted in meetings with investment firms, representatives from Big Pharma, important contacts with Key Opinion Leaders, and prominent researchers in the field.

AD/PD™ - International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders - is an international conference for neurodegenerative diseases, which this year was held in Gothenburg on March 28 - April 1. The AD/PD™ conference is a highly regarded scientific forum for neurodegenerative diseases and attracts leading medical and scientific experts from around the world. At this year's conference, which was characterized by optimism, Alzinova noted great interest in vaccines and their advantages over the antibodies that are currently approved or under development. Above all, it was emphasized that vaccines are more patient-friendly and cost-effective treatments, which may make it possible for many more people to receive an effective treatment for Alzheimer's disease.

Potential disease-modifying therapies against the amyloid-beta peptide were discussed extensively during the conference, with many expecting them to become the standard of care for Alzheimer's disease. Another field that attracted great interest is biomarkers where great progress is being made, which for Alzinova's part could open up new methods for recruiting patients and, in the future, also enable the development of a preventive treatment where basically healthy individuals are vaccinated before the disease has progressed.

The poster is available on Alzinova's website <https://www.alzinova.com/investors/presentations/>



For more information, please contact:

Kristina Torfgård, CEO

Tel. +46 708 46 79 75

E-mail: kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A β CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Attachments

Interest from potential partners and positive response to ALZ-101 at the AD/PD™ conference